Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 24Phase 1 19Phase 1/2 12Phase 4 4Phase NA 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4Solid Tumors 1

Interventions

Letrozole 20Docetaxel 16Cyclophosphamide 13Zoledronic Acid 12exemestane 11Trastuzumab 11Anastrozole 11Paclitaxel 10Tamoxifen 9Capecitabine 9Fulvestrant 8Epirubicin 8pegfilgrastim 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Saline Solution 6palbociclib 5Sodium Chloride 5Dexmedetomidine 5Carboplatin 5Bupivacaine 5Bevacizumab 5ribociclib 4pegylated granulocyte colony-stimulating factor 4eribulin 4Tranexamic Acid 4Standard of Care 4Pamidronate 4Filgrastim 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Breast Neoplasms × ribociclib × Clear all
NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Novartis

Phase 4 Active not recruiting
134 enrolled
Breast

Breast Neoplasms

NCT07487129 2026-03-23

Clinical and P

Beni-Suef University

Phase 4 Completed
206 enrolled
Breast

Breast Neoplasms

NCT04657679 2024-11-26

LEANORA

Georgetown University

Phase 4 Terminated
21 enrolled 19 charts
Breast

Breast Neoplasms

NCT05452213 2023-04-18

CAPTOR-BC

Institut fuer Frauengesundheit

Phase 4 Recruiting
1,000 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡